What did @vsgdocumentary actually say?
At week 12 on Wegovy (semaglutide), Sharon says she moved up to a higher dose and noticed her appetite suppression slipping. "The food noise is back. The temptation is getting to me," she tells viewers directly. She describes eating bread and butter at Texas Roadhouse, snacking more than she wanted, ordering Wingstop wings, and eating a slice of pound cake, and connecting that behavior to still being on a lower dose (1.5 mg) before her upcoming 4 mg step-up. She frames the overeating as her own fault but also links relief to the next dose increase.
She also makes an implicit claim that higher doses of semaglutide will restore appetite control, and that the current dose is no longer holding. That's the core assertion worth examining.
Does the science back this up?
Yes, mostly. The dose-dependent appetite suppression of semaglutide is well-documented, and appetite returning before a dose increase is a real, observed pattern. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that higher doses of semaglutide produced greater reductions in appetite and body weight, with the 2.4 mg weekly maintenance dose outperforming lower doses across the board.
More relevant here: GLP-1 receptor agonists work in part by acting on hypothalamic appetite centers and slowing gastric emptying. When plasma drug concentrations dip, or when a patient is still titrating, that suppression weakens. A 2022 analysis by van Can et al. in Obesity Reviews noted that patient-reported food cravings and hunger often resurface during titration phases before therapeutic steady-state levels are reached. Sharon's experience at week 12 on 1.5 mg, before stepping up, fits that pattern reasonably well.
What did they get wrong (or right)?
She got the core biology right. Dose-dependent suppression of appetite is real, and blaming the 1.5 mg dose for weakened appetite control at week 12 is a plausible explanation, not just rationalization. Credit where it's due.
What she glosses over: the pound cake, Texas Roadhouse bread, and snacking weren't purely pharmacological failures. The behavioral and environmental triggers, a travel weekend, family social eating, a husband buying dessert, matter a lot. Research by Tronieri et al. (2020, International Journal of Obesity) found that even patients on semaglutide show higher caloric intake in socially stimulating or high-reward food environments. The drug reduces food noise, it does not eliminate environmental cues or emotional eating entirely at any dose.
She also says "that was my fault" about the stomach ache, which is accurate. Eating high-fat, high-volume meals on semaglutide frequently causes GI distress because gastric emptying is already slowed. That self-awareness is honest and correct.
What should you actually know?
If you're on a GLP-1 medication and notice appetite returning mid-titration, that is not unusual and it does not mean the medication stopped working permanently. Steady-state plasma levels take time to establish after each dose increase, and many patients report a temporary window of reduced efficacy between steps.
However, relying entirely on the next dose to fix eating behavior is a setup for frustration. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) found that patients who combined semaglutide with structured behavioral support maintained significantly better outcomes than those who did not. The drug is a tool, not a switch. Social eating situations, travel, and high-reward foods will still challenge most patients at almost any dose.
The stomach ache Sharon describes is also worth flagging. Eating fatty, large-volume meals while on a GLP-1 medication is a common cause of nausea and GI discomfort. It is not dangerous in most cases, but it is avoidable. Smaller portions, lower fat intake, and slower eating consistently reduce GI side effects across published titration guidelines.
- Dose-dependent appetite suppression is real, but it does not override environmental or behavioral triggers.
- GI symptoms after high-fat meals on semaglutide are predictable and preventable.
- Mid-titration appetite return is documented and not necessarily a sign of treatment failure.